Bionow

November Bionow Newlsetter

1 December 2011

Bionow News

Bionow announce winners of the 2011 Bionow Annual Awards Bionow are delighted to announce the winning companies, projects and individuals of the 2011 Bionow Annual Awards Dinner. This prestigious event took place on Thursday 24th November at The Mere Golf & Country Club.

The 2011 winners are:-
Bionow Company of the Year - Sponsored by AstraZeneca
Winner: Qiagen

Biomedical Product or Service of the year- Sponsored by Kaplan EduNeering
Winner: Geko, Sky Medical Technology

Startup Company of the Year - Sponsored by Baker Tilly
Winner: Redx Pharma

Promising Biomedical Technologist of the Year - Sponsored by Novartis Vaccines
Winner: Jonathan Souquet, Eden Biodesign

Biomedical Project of the Year - Sponsored by Semple Fraser
Winner: MycAssay series of real-time PCR products, Myconstica Ltd

Emerging Biomedical Technology Project of the Year - Sponsored by Waters Corporation
Winner: Conformetrix, Conformetrix Ltd

Healthcare Project of the Year - Sponsored by Trustech
Winner: Evaluation of a new point of care coagulation monitor, Microvisk Technologies

News

Green light for Redx cancer drugs research unit
Plans to develop a state-of-the-art drug research centre in Liverpool took a significant step forward on 1 November with the award of £5.9m from the Government's Regional Growth Fund to support a project which will create up to 250 bioscience jobs in the city. Redx Pharma Ltd has received a conditional offer letter for the grant, following an announcement made by Deputy Prime Minister Nick Clegg. The investment will help to finance an initial two-year research and development phase into promising new drugs for the treatment of cancer.

Ebiox raises funds to support further growth
Medical and hygiene products developer Ebiox has raised £700,000 to support its further growth. The company commented that the rights issue would 'strengthen its balance sheet and provide further working capital funding to grow the business'. Ebiox produces decontamination products designed to assist in the control of potentially harmful pathogens and reduce the risk of cross infection in hospitals and other clincal environments.

Epistem raises £2.8m to roll out Genedrive
Epistem is to raise £2.8m to fund the roll-out of its Genedrive device. The company is to raise the money through a placing at 350p per share. It is placing 793,398, which is equivalent to around 10% of it existing share capital. Genedrive is a portable device which can be used to provide a molecular diagnosis of patient samples, meaning that diseases or cancers can be diagnosed in remote locations within 20 minutes.
Also, Epistem announced a partnership with Dr Matthew Hardman at The University of Manchester in which novel preclinical models for cutaneous wound healing, developed within Dr Hardman's laboratory, will be transferred to Epistem. Epistem and The University of Manchester have been awarded a Knowledge Transfer Partnership grant from the Technology Strategy Board and Medical Research Council to optimise, validate and commercialise new preclinical assays for wound repair.

Biomedical fund invests in Albert Medical
Albert Medical Devices, which develops products for the urology sector, has secured an investment from the £25m North West Fund for Biomedical as part of a £210,000 funding round. The company has been awarded a £50,000 Pathfinder Investment from the fund which will be used to take on new members of staff and begin manufacturing its Melio product. The device is a discreet aid for self-managing urinary incontinence.

Sinclair IS Pharma sells £11m drug
Pharmceutical company Sinclair IS Pharma has sold Mysoline, a drug used to treat epilepsy, for £11.1m in cash. The company, which has sold the drug to Laboratories Serb SAS of France, commented that the move was in line with its strategy to dispose of non-strategic assets and focus on dermatology, wound care and its hospital supportive care products.

Assura raises £110m
Primary care property company Assura Group has raised £110m through a ten-year bond. The money was raised through the issuance of a ten-year senior secured bond at a fixed rate coupon of 4.75 per cent. It was raised via its subsidiary Assura Properties. The bond finance aims to help the company repay a loan from National Australia Bank that was due to mature in March 2013.

Biomedical fund invest £100,000 in a further two companies
The University of Salford's first ever drug development spin-out company Onco-NX has secured a £50,000 pathfinder investment, while Manchester-based Kanichi Research Services, a developer of sensors for the healthcare market, has also received £50,000. Dr Penny Attridge, senior investment manager at Spark Impact, said 'Spark Impact is continuing to invest in exciting and interesting opportunities, over the last few months we have completed six pathfinder investments across the very wide and diverse biomedical sector.

Renovo board to consider all options
Renovo's chairman Mark Ferguson has said the business is considering 'all options available to it'. Professor Ferguson said 'Renovo is well funded and its future strategy is aimed at maximising shareholder value. The company will consider all options available to it which may include acquisitions and mergers of external companies in addition to realising value from its current intellectual property portfolio where possible.

One Nucleus, Bionow and SEHTA working in collaboration to bring international benefits with a local touch
A significant collaboration between three of the leading life science membership organisations will be showcased at the Genesis Conference. One Nucleus, Bionow and SEHTA will all present within the Bringing it ON ZONE where delegates will have the opportunity to meet with a selection of the Preferred Suppliers, expert trainers and data providers working with these three organisations to deliver value to their respective members.

Cyprotex improves drug testing software
Drug testing company Cyprotex has completed a major upgrade of the software it uses to predict pharmacokinetic changes caused by drug compounds. The company said the Cloe PK software has already been shown to be able to predict via computer modelling aspects of human pharmacokinetics better than extrapolating results from studies using animals.

Recruitment

Ai2 Ltd - Research Scientist
Ai2 Ltd is an award-winning company specialising in novel anti-infective peptide technology. An exciting opportunity has arisen for a Research Scientist. The successful applicant will be required to undertake work on projects aimed at developing Ai2’s technology for applications in commercial opportunities. This position would suit a candidate with a PhD in microbiology, ideally oral microbiology. For further information on this post, please click here. Closing date – Friday 9th December 2011.

Ai2 Ltd - Research Technician
Ai2 Ltd also has a fantastic opportunity for a Research Technician. The successful candidate will be required to undertake microbiological experimental work in addition to providing technical support for current staff on a number of ongoing research projects in addition to more general housekeeping duties such as preparation of media/buffers, ordering, stock control, etc. For further information on this post, please click here. Closing date – Friday 9th December 2011.

PhD Studentship -Institute for Materials Research & Innovation (3.5 years duration)
Applications are invited for an EPSRC Industrial CASE PhD studentship, awarded via the Materials Knowledge Transfer Network, to join the Auxetic Materials Research Group within the Institute for Materials Research & Innovation (IMRI) at the University of Bolton in collaboration with Central Manchester NHS Foundation Trust. The studentship, available immediately, will investigate the use of auxetic materials in biomedical devices for laparoscopic surgery and related procedures to develop new surgical devices to benefit patients. Prospective candidates can contact Professor Andy Alderson, Director of IMRI (Tel: 01204 903513, email: a.alderson@bolton.ac.uk) for an informal discussion relating to this opportunity.

Qiagen Manchester - Current Opportunities
Qiagen is the world's leading provider of molecular sample and assay technologies. The company has developed and marketed more than 500 products in 40 countries that help healthcare professionals to detect and prevent diseases, predict patient responses and enable researchers to achieve scientific breakthrough. Qiagen is one of the most innovative and fastest growing companies in life sciences with over 3200 employees in more than 30 countries. If you are interested in becoming part of a dynamic and enthusiastic multinational team, please click here to view the latest opportunities.

Eden Biodesign - Current Opportunities
Eden Biodesign operates a £34million world-class facility designed to allow rapid and low cost manufacture of the widest range of high quality biopharmaceutical products. To support their growing client base and expanding project portfolio they are currently seeking world class scientists, engineers and specialists with the relevant skills and experience in biopharmaceuticals. If you believe you possess the personality and skills to contribute to Eden Biodesign's continued growth and success, please visit http://www.edenbiodesign.com/join-us.php for further information on current opportunities or email annette.england@edenbiodesign.com.

SRG - Bionow Preferred Recruitment Provider
SRG is the UK's leading supplier of scientific, clinical, quality, regulatory, technical and engineering staffing solutions to the broad based science community. Having pioneered the scientific contract market in 1990, SRG has expanded its offering from providing traditional contract and permanent recruitment services through to bespoke out-sourced resource solutions. For further information and to view the latest vacancies please contact the SRG team on 0161 868 2200 or email Mark Bustos at Mark.Bustos@srg.co.uk.

Events

An introduction to Drug Development - 16th December
An introduction to drug development has been designed to introduce delegates to the process leading from an initial discovery through to the marketing of a drug. The aim of the programme is to show how the many steps are linked together and where key related activites such as patenting, licensing and fund-raising have to be taken into account. This interactive course is a fantastic opportunity to introduce recent recruits and those who are not currently familiar with the 'bigger picture' of drug discovery. For further information and to register, please click here.

Beyond Digital Health Manchester 2011 - 13th/14th December
MIDAS is hosting the inaugural Beyond Digital Health Manchester 2011. This FREE conference and exhibition will look at eHealth, mHealth, personalised medicine, assisted living and remote diagnostics from the perspective of businesses, investors, policy makers and service deliverers with an emphasis on collaboration across sectors. For the full conference programme and to register, please visit click here.

Bionow Network Evening - 13th December
'The Science of Persuasion' will be the theme at the next Bionow network evening. We are delighted to have Beth Curl from Hyproformance Ltd hosting this interative session which will explore Robert Cialidini's 6 principles of influence and discover how we can use them to persuade people ethically, so that we can achieve more in both our professional and personal lives. For further information and to register, please click here

Liverpool Innovation Park Tech Exec Breakfast - 'Capitalising on Healthcare' - 7th December
Dr Brian White, Head of Healthcare at Shore Capital Stockbrokers, will discuss the current market environment for healthcare & the challenges it faces at this FREE event. With an extensive background in pharma & biotechnology investments, Dr White will identify the individual sub-sectors providing significant investment opportunities & explain why investment in healthcare is both more popular & important. For further information and to register, please click here.

Company Registered Address:
Bionow Ltd, Kilburn House, Lloyd Street North, Manchester, M15 6SE
Company Limited by Guarantee. Registered in England and Wales. Number 07415429 Disclaimer:

The Information contained above is taken from public domain sources. Whilst we endeavour to ensure that the information is factual, Bionow accepts no responsibility for any errors. Opinions, conclusions and other information in this message that do not relate to the official business of the Bionow shall be understood as neither given nor endorsed by it. Unsubscribe